|
KMID : 0988920220200010150
|
|
Intestinal Research
2022 Volume.20 No. 1 p.150 ~ p.155
|
|
|
Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report
|
|
Koroku Miki
Omori Teppei
Kambayashi Harutaka
Murasugi Shun
Kuriyama Tomoko
Ikarashi Yuichi
Yonezawa Maria
Arimura Ken
Karasawa Kazunori
Hanafusa Norio
Kawana Masatoshi
Tokushige Katsutoshi
|
|
|
Abstract
|
|
|
|
Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.
|
|
|
KEYWORD
|
|
|
COVID-19, Granulocyte and monocyte adsorptive apheresis, Ulcerative colitis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|